ArticleNature communications2024
Reprogramming the myocardial infarction microenvironment with melanin-based composite nanomedicines in mice.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Bioadaptive spatiotemporal nanomedicine promotes metabolic recovery after myocardial infarction through NADNature cardiovascular research · 2026Article
- Spatiotemporal iron-hijacking hydrogel reprograms host-pathogen iron homeostasis for fungal keratitis therapy.Cell reports. Medicine · 2026Article
- Precision inflammation targeting via myeloperoxidase mediated antioxidant melanin nanomedicines for chronic inflammation therapy.Nature communications · 2026Article
- Injectable Microenvironment-Responsive Hydrogel for Local Procyanidin B2 Delivery and Cardiac Ischemia-Reperfusion Repair.ACS applied materials & interfaces · 2026Article
- Research advances in intelligent microenvironment-responsive hydrogels for myocardial infarction therapy.APL bioengineering · 2026Review
- Asymmetric nanozymes improve cardiac purine catabolism and alleviate oxidative stress of myocardium to treat ischemic heart disease.Journal of nanobiotechnology · 2026Article
- Hyaluronic acid engineered melanin-MOF nanoreactor synergistically remodeling redox and immune homeostasis for targeted acute lung injury therapy.Materials today. Bio · 2026Article
- Recent Progress and Morphological Distribution of Polydopamine-Based Biomaterials and Their Applications.Gels (Basel, Switzerland) · 2026Review
- Injectable BMSC-Based Extracellular Matrix-Mimicking Microtissue for Myocardial Infarction Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Biomimetic dynamic nanomedicine SrHCF: Lattice self-reconstruction based on FeBioactive materials · 2026Article
- Multifunctional microneedle patch loaded with microfluidic-synthesized hybrid gas-nanozyme for myocardial infarction treatment.Journal of nanobiotechnology · 2025Article
- Engineered metallic hybrid nanozyme for advanced inflammatory disease therapy.Materials today. Bio · 2025Review
- Polydopamine Nanodots Ameliorate Inflammatory Bowel Disease by Restoring Redox Homeostasis and Intestinal Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Polydopamine as a biocompatible and precise mitochondrial targeted therapeutic platform for reversing myocardial ischemia-reperfusion injury.Bioactive materials · 2025Article
- Advancements in nanomedicine for modulating ischemic cardiomyopathy therapy.Materials today. Bio · 2025Review
- CD11b-modified ROS/pH-responsive nanoparticles co-deliver Dioscin and siRNA to improve cardiac repair after myocardial infarction by reducing neutrophil recruitment.Materials today. Bio · 2025Article
- Inflammatory Responses Potentiate GAS M Protein Induced Cardiac Damage in an Experimental Model of Rheumatic Heart Disease.Immunity, inflammation and disease · 2025Article
- Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy.Molecular cancer · 2025Review
- Nanomedicine Penetrating Blood-Pancreas Barrier for Effective Treatment of Acute Pancreatitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Iron chelators loaded on myocardiocyte mitochondria-targeted nanozyme system for treating myocardial ischemia-reperfusion injury in mouse models.Journal of nanobiotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Myocardial infarction (MI) has a 5-year mortality rate of more than 50% due to the lack of effective treatments. Interactions between cardiomyocytes and the MI microenvironment (MIM) can determine the progression and fate of infarcted myocardial tissue. Here, a specially designed Melanin-based composite nanomedicines (MCN) is developed to effectively treat MI by reprogramming the MIM. MCN is a nanocomposite composed of polydopamine (P), Prussian blue (PB) and cerium oxide (Ce
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.